PL2923208T3 - Sposoby określania ryzyka ostrej choroby przeszczep przeciwko gospodarzowi - Google Patents

Sposoby określania ryzyka ostrej choroby przeszczep przeciwko gospodarzowi

Info

Publication number
PL2923208T3
PL2923208T3 PL13792933T PL13792933T PL2923208T3 PL 2923208 T3 PL2923208 T3 PL 2923208T3 PL 13792933 T PL13792933 T PL 13792933T PL 13792933 T PL13792933 T PL 13792933T PL 2923208 T3 PL2923208 T3 PL 2923208T3
Authority
PL
Poland
Prior art keywords
risk
determining
methods
host disease
versus host
Prior art date
Application number
PL13792933T
Other languages
English (en)
Inventor
Olivier Hermine
Marie Thérèse RUBIO
Marie BOUILLIE
Maria LEITE DE MORAES
Original Assignee
Institut National De La Santé Et De La Recherche Médicale (Inserm)
Centre National De La Recherche Scientifique (Cnrs)
Assistance Publique Hôpitaux De Paris
Université Paris Descartes
Imagine Institut Des Maladies Génétiques Necker Enfants Malades
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut National De La Santé Et De La Recherche Médicale (Inserm), Centre National De La Recherche Scientifique (Cnrs), Assistance Publique Hôpitaux De Paris, Université Paris Descartes, Imagine Institut Des Maladies Génétiques Necker Enfants Malades filed Critical Institut National De La Santé Et De La Recherche Médicale (Inserm)
Publication of PL2923208T3 publication Critical patent/PL2923208T3/pl

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047Cells of the immune system
    • G01N33/505Cells of the immune system involving T-cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966Animal cells
    • G01N33/56972White blood cells
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52Assays involving cytokines
    • G01N2333/54Interleukins [IL]
    • G01N2333/55IL-2
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/7051T-cell receptor (TcR)-CD3 complex
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70514CD4
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/24Immunology or allergic disorders
    • G01N2800/245Transplantation related diseases, e.g. graft versus host disease
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/50Determining the risk of developing a disease
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Transplantation (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
PL13792933T 2012-11-21 2013-11-21 Sposoby określania ryzyka ostrej choroby przeszczep przeciwko gospodarzowi PL2923208T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12306445 2012-11-21
PCT/EP2013/074407 WO2014079946A1 (en) 2012-11-21 2013-11-21 Methods for determining the risk of acute graft versus host disease
EP13792933.7A EP2923208B1 (en) 2012-11-21 2013-11-21 Methods for determining the risk of acute graft versus host disease

Publications (1)

Publication Number Publication Date
PL2923208T3 true PL2923208T3 (pl) 2019-09-30

Family

ID=47297066

Family Applications (1)

Application Number Title Priority Date Filing Date
PL13792933T PL2923208T3 (pl) 2012-11-21 2013-11-21 Sposoby określania ryzyka ostrej choroby przeszczep przeciwko gospodarzowi

Country Status (10)

Country Link
US (1) US10151745B2 (pl)
EP (1) EP2923208B1 (pl)
JP (1) JP6599233B2 (pl)
CN (1) CN105122067B (pl)
AU (1) AU2013349706B2 (pl)
CA (1) CA2892482C (pl)
DK (1) DK2923208T3 (pl)
ES (1) ES2719255T3 (pl)
PL (1) PL2923208T3 (pl)
WO (1) WO2014079946A1 (pl)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7184299B2 (ja) 2017-04-28 2022-12-06 健一 山田 低密度リポタンパク質の酸化状態および糖化状態を識別するための検出試薬およびキット
JP6943386B2 (ja) 2017-04-28 2021-09-29 山田 健一 脂質由来のラジカル体の検出方法およびラジカル体由来の化合物
JP2020526218A (ja) * 2017-07-14 2020-08-31 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 移植拒絶リスクを予測する新規の方法
CN107831225B (zh) * 2017-10-13 2021-08-10 苏州大学附属第一医院 硬脂酸/软脂酸组合作为aGVHD疾病诊断标志物的应用
IL276365B2 (en) 2018-02-01 2023-10-01 Nkmax Co Ltd A method for the production of natural killer cells and a preparation for cancer treatment
EP3764877A4 (en) 2018-03-12 2021-12-15 The Regents of The University of California EVALUATION OF TRANSPLANT REJECTION STATUS BY ANALYSIS OF DIVERSITY OF T-CELL RECEPTOR SUBUNIT REPERTOIRE
CN111208223B (zh) * 2020-01-13 2023-01-17 浙江大学 心脏死亡后捐献受体术前预警移植肾延迟复功的代谢物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0559081A (ja) 1991-08-29 1993-03-09 Kirin Brewery Co Ltd 新規スフインゴ糖脂質、その製造法および使用
TW261533B (pl) 1992-07-16 1995-11-01 Kirin Brewery
AU683026B2 (en) 1992-10-22 1997-10-30 Kirin Pharma Kabushiki Kaisha Novel shingoglycolipid and use thereof
EP0694558B1 (en) 1993-04-15 1999-01-27 Kirin Beer Kabushiki Kaisha Novel sphingoglycolipid and use thereof
JP3495740B2 (ja) 1997-04-10 2004-02-09 麒麟麦酒株式会社 α−グリコシルセラミドを含有するNKT細胞活性化剤
US20050069546A1 (en) * 2003-09-30 2005-03-31 Yaron Ilan Educated NKT cells and their uses in the treatment of immune-related disorders
WO2009062160A2 (en) 2007-11-08 2009-05-14 Children's Medical Center Corporation Rantes levels as a diagnostic and therapeutic for acute graft versus host disease
CN101402941A (zh) * 2008-11-11 2009-04-08 章毅 从脐带血中扩增Vα24NKT细胞的方法
DE102010037622B4 (de) * 2010-09-17 2012-07-12 Lophius Biosciences Gmbh Verfahren zum Nachweis, Differenzieren und Quantifizieren von T-Zellpopulationen mittels der Reverse Transkription quantitativen Real-Time PCR (RT-qPCR) Technologie

Also Published As

Publication number Publication date
CN105122067B (zh) 2017-07-11
CA2892482C (en) 2022-11-08
EP2923208A1 (en) 2015-09-30
ES2719255T3 (es) 2019-07-09
DK2923208T3 (en) 2019-04-15
AU2013349706A1 (en) 2015-06-11
EP2923208B1 (en) 2019-01-16
CA2892482A1 (en) 2014-05-30
AU2013349706B2 (en) 2019-08-22
WO2014079946A1 (en) 2014-05-30
US10151745B2 (en) 2018-12-11
CN105122067A (zh) 2015-12-02
JP6599233B2 (ja) 2019-10-30
US20150301022A1 (en) 2015-10-22
JP2016503302A (ja) 2016-02-04

Similar Documents

Publication Publication Date Title
IL243976B (en) kdm1a inhibitors for disease treatment
IL235512A0 (en) New methods
GB201505407D0 (en) Methods for discovering therapeutic targets
AU350549S (en) Breathalyzer
EP3041576A4 (en) Methods for detecting renal disease
ZA201408955B (en) Anti-blys antibody
EP2808681A4 (en) breathalyser
ZA201406925B (en) Biocontrol
EP2870158A4 (en) PROTEIN KINASE INHIBITORS
AU345873S (en) Pan
GB2506114B (en) Boot
GB201214440D0 (en) Kidney disease biomarker
EP2855484A4 (en) PROTEIN KINASE INHIBITORS
PL2923208T3 (pl) Sposoby określania ryzyka ostrej choroby przeszczep przeciwko gospodarzowi
IL236132B (en) Uoglobulin-based method for determining the biological activity of defibrotide
ES2687237T8 (es) Dispositivo de suspensión para muebles de pared
EP2891923A4 (en) TONER
GB201201132D0 (en) Automatic determining of file transfer mode
GB201317621D0 (en) Kidney disease biomarker
GB201208910D0 (en) Emulsion
SG10201704145RA (en) Biotinylated protein
GB201213672D0 (en) Protein
GB201215268D0 (en) Boot heater
GB201212144D0 (en) Blood rey rooters
GB2525829B (en) Drum mallet